508 related articles for article (PubMed ID: 28481356)
1. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.
Nag S; Trivedi DV; Sarkar SS; Adhikari AS; Sunitha MS; Sutton S; Ruppel KM; Spudich JA
Nat Struct Mol Biol; 2017 Jun; 24(6):525-533. PubMed ID: 28481356
[TBL] [Abstract][Full Text] [Related]
2. β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity.
Adhikari AS; Trivedi DV; Sarkar SS; Song D; Kooiker KB; Bernstein D; Spudich JA; Ruppel KM
Nat Commun; 2019 Jun; 10(1):2685. PubMed ID: 31213605
[TBL] [Abstract][Full Text] [Related]
3. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
[TBL] [Abstract][Full Text] [Related]
4. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.
De Lange WJ; Grimes AC; Hegge LF; Spring AM; Brost TM; Ralphe JC
J Gen Physiol; 2013 Sep; 142(3):241-55. PubMed ID: 23980194
[TBL] [Abstract][Full Text] [Related]
5. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
[TBL] [Abstract][Full Text] [Related]
6. The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin.
Sarkar SS; Trivedi DV; Morck MM; Adhikari AS; Pasha SN; Ruppel KM; Spudich JA
Sci Adv; 2020 Apr; 6(14):eaax0069. PubMed ID: 32284968
[TBL] [Abstract][Full Text] [Related]
7. Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy.
Kraft T; Montag J
Pflugers Arch; 2019 May; 471(5):719-733. PubMed ID: 30740621
[TBL] [Abstract][Full Text] [Related]
8. Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue.
Wijnker PJM; van der Velden J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165774. PubMed ID: 32217077
[TBL] [Abstract][Full Text] [Related]
9. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
[TBL] [Abstract][Full Text] [Related]
10. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C.
Gruen M; Gautel M
J Mol Biol; 1999 Feb; 286(3):933-49. PubMed ID: 10024460
[TBL] [Abstract][Full Text] [Related]
11. Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition.
Robert-Paganin J; Auguin D; Houdusse A
Nat Commun; 2018 Oct; 9(1):4019. PubMed ID: 30275503
[TBL] [Abstract][Full Text] [Related]
12. Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes.
McNamara JW; Li A; Smith NJ; Lal S; Graham RM; Kooiker KB; van Dijk SJ; Remedios CGD; Harris SP; Cooke R
J Mol Cell Cardiol; 2016 May; 94():65-71. PubMed ID: 27021517
[TBL] [Abstract][Full Text] [Related]
13. Structural effects of the slow/b-cardiac myosin heavy chain R453C mutation in cardiac and skeletal muscle.
Tajsharghi H; Fyhr IM
Scand Cardiovasc J; 2008 Apr; 42(2):153-6. PubMed ID: 18365899
[TBL] [Abstract][Full Text] [Related]
14. Incomplete-penetrant hypertrophic cardiomyopathy
Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
[TBL] [Abstract][Full Text] [Related]
15. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
16. A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy.
Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Kärkkäinen S; Peuhkurinen K; Nieminen MS; Laakso M; ; Kuusisto J
Ann Med; 2014 Sep; 46(6):424-9. PubMed ID: 24888384
[TBL] [Abstract][Full Text] [Related]
17. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
[TBL] [Abstract][Full Text] [Related]
18. Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.
Ujfalusi Z; Vera CD; Mijailovich SM; Svicevic M; Yu EC; Kawana M; Ruppel KM; Spudich JA; Geeves MA; Leinwand LA
J Biol Chem; 2018 Jun; 293(23):9017-9029. PubMed ID: 29666183
[TBL] [Abstract][Full Text] [Related]
19. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
